328
Participants
Start Date
May 8, 2017
Primary Completion Date
May 21, 2018
Study Completion Date
May 21, 2018
Use of digital disease management tool
The purpose of the study is to evaluate if the provision of a digital disease management tool, in addition to SOC for T2DM, will improve glycemic control. The impact of the tool will be assessed in comparison to a Control group who will receive SOC alone. All participants will complete the PRO assessments. This is a real world study carried out at the point of care.
Research Site, Brooklyn
Research Site, New Windsor
Research Site, Westfield
Research Site, Downingtown
Research Site, Manassas
Research Site, Oxon Hill
Research Site, Burke
Research Site, Richmond
Research Site, Greensboro
Research Site, Spartanburg
Research Site, Charleston
Research Site, Myrtle Beach
Research Site, Greer
Research Site, Lake City
Research Site, Port Orange
Research Site, Ormond Beach
Reserarch Site, Jacksonville
Research Site, DeLand
Research Site, Hialeah
Research Site, Cooper City
Research Site, Pembroke Pines
Research Site, Tampa
Research Site, Birmingham
Research Site, Birmingham
Research Site, Tullahoma
Research Site, Lexington
Research Site, Franklin
Research Site, Evanston
Research Site, Omaha
Research Site, Plano
Research Site, Lampasas
Research Site, Houston
Research Site, Houston
Research Site, Colorado Springs
Research Site, Salt Lake City
Research Site, Surprise
Research Site, Peoria
Research Site, Albuquerque
Research Site, Las Vegas
Research Site, Van Nuys
Research Site, North Hollywood
Resezrch Site, Montclair
Research Site, Spring Valley
Research Site, Lincoln
Research Site, Federal Way
Research Site, Olympia
Lead Sponsor
AstraZeneca
INDUSTRY